COX-2 inhibitor use after Vioxx: Careful balance or end of the rope?

American Journal of Managed Care

Volumn 10, Issue 11 I, 2004, Pages 740-741

  Fendrick, A Mark ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

DRUG DOSE REGIMEN; DRUG PREFERENCE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

CEREBROVASCULAR ACCIDENT; CYCLOOXYGENASE INHIBITORS; DRUG INDUSTRY; HUMANS; LACTONES; MYOCARDIAL INFARCTION; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; SAFETY; SULFONES; UNITED STATES;

EID: 8744262936     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA. Appropriateness of NSAID and coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: Results from the CANOAR study. Am J Manag Care. 2004;10: 742-750.
2. Solberg LI, Hurley JS, Roberts MH, et al. Measuring patient safety in ambulatory care: Potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care. 2004;10:753-759.
3. Fick DM, Maclean, JR, Rodriguez NA, et al. A randomized study to decrease the use of potentially inappropriate medications among community-dwelling elderly adults in a southeastern managed care organization. Am J Manag Care. 2004;10:761-768.
4. Parente ST, Kim SS, Finch MD, et al. Identifying patterns of controlled substance utilization requiring evaluation using administrative claims data. Am J Manag Care. 2004;10:783-790.
5. Merck announces voluntary worldwide withdrawal of VIOXX® [press release]. Whitehouse Station, NJ. September 30, 2004. Available at: http://www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp. Accessed October 28, 2004.
6. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med. 2004 Oct 21;351(17):1707-1709.
7. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004 Oct 21;351(17):1709-1711.
8. National Cholesterol Education Program. Risk Assessment Tool for Estimating 10-year Risk of Developing Hard CHD. Available at: http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof. Accessed Oct. 14, 2004.
9. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA. 2000;284: 1247-1255.
10. Schnitzer TJ, Burmester GR, Mysler, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004 Aug 21;364(9435):665-674.
11. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004 Aug;127(2):395-402
12. Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med. 2004 Jun 14;164(11):1243-1246.
13. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002 Dec 26;347(26):2104-2110.
14. Fendrick AM, Garabedian-Ruffalo SM. A clinician's guide to the selection of NSAID therapy. P&T. 2002;27:579-582.